Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children

详细信息	查看全文 | 推荐本文 |

• 作者：Carlos Castañ ; eda-Orjuela^a ; ^{cacastanedao@unal.edu.co} ; ^{carloscastanedao@gmail.com} ; Nelson Alvis-Guzmá ; n^b ; ¹ ; ^{nalvis@yahoo.com} ; Martha Velandia-Gonzá ; lez^c ; ^{mvelandia@minproteccionsocial.gov.co} ; Fernando De la Hoz-Restrepo^a ; ^{fpdelahozr@unal.edu.co}
• 关键词：AOM ; acute otitis media ; EPI ; expanded program of immunization ; IPD ; invasive pneumococcal disease ; PCV ; pneumococcal conjugated vaccine ; RX pneumonia ; radiologically confirmed pneumonia
• 刊名：Vaccine
• 出版年：2012
• 期刊代码：89_0264410x
• 类别：imm
• 出版时间：2 March, 2012
• 卷：30
• 期：11
• 页码：1936-1943
• 文件大小：597 K

摘要

Background

Currently there are three pneumococcal conjugate vaccines with different coverage of serotypes for use in children under one year. We evaluate the cost-effectiveness of the introduction of pneumococcal conjugate vaccines of 7, 10, and 13 valences in the Colombian EPI.

Methods

A Markov model, which followed a cohort of children under one year to life expectancy, was developed. Parameters of occurrence and care costs were based on data from National Health System and literature review. PCV-7 is a dominated strategy. PCV-10 and PCV-13 were each compared to no vaccination or PCV-10 vaccination, respectively. A 2 + 1 schedule and a vaccination price of US$ 14.00, US$ 14.85 and US$ 16.34 per dose were assumed in the base case for PCV-7, -10, and PCV-13 vaccines.

Results

Introduction of PCV-13 rather than PCV-10 increases the number of life years gained (LYG). From the societal perspective, in the 鈥榗ompeting choice鈥?framework cost per LYG was US$ 1837 with PCV-10 and US$ 9514 with PCV-13, while PCV-7 is a dominated strategy. The ICER of PCV-13 is above the per capita Gross Domestic Product. Incremental cost-effectiveness ratios (ICERs) were influenced mainly by effectiveness against radiologically-confirmed pneumonia and AOM, vaccine price, and discount rate.

Conclusion

Routine vaccination against Streptococcus pneumoniae in Colombia would be cost-effective with PCV-10, with ICER below the per-capita GDP, but its inclusion requires evaluating the budget impact. PCV-13 would prevent more disease and deaths with a higher LYG, but PCV-10 would save more cost to the healthcare system due its higher impact in the prevention of AOM. There is limitation in the clinical evidence of both strategies.